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use of GFP-based constructs is limited to cells that can
be efficiently transfected. Additionally, DNA transfection
protocols often require several days to produce cells
Shelley R. Starck,1 Harry M. Green,2
Jose´ Alberola-Ila,2 and Richard W. Roberts1,*
1Division of Chemistry and Chemical Engineering
2Division of Biology yielding robust GFP-based fluorescent signals and also
inundate the protein synthesis machinery with a nonna-California Institute of Technology
1200 E. California Boulevard tive transcript due to the use of strong upstream promot-
ers. Finally, transfection-based strategies generally re-Pasadena, California 91125
quire choice of a particular candidate gene product.
We reasoned that puromycin-based reagents might
provide a general means to examine protein expression.Summary
Puromycin is a structural analog of aminoacylated-tRNA
(aa-tRNA) and participates in peptide-bond formationUnderstanding the expression of known and unknown
with the nascent polypeptide chain (Figure 1A) [12, 13].gene products represents one of the key challenges
Previously, various puromycin derivatives of the formin the post-genomic world. Here, we have developed
X-dC-puromycin have been examined and shown to bea new class of reagents to examine protein expression
functional during in vitro translation experiments [14–in vivo that does not require transfection, radiolabel-
17]. In principle, a fluorescent or biotinylated varianting, or the prior choice of a candidate gene. To do
of puromycin should be functional in protein synthesisthis, we constructed a series of puromycin conjugates
in vivo if it is able to enter cells in a nondestructivebearing various fluorescent and biotin moieties. These
fashion (Figure 1B). In this way, selective labeling ofcompounds are readily incorporated into expressed
newly synthesized proteins would enable direct monitor-protein products in cell lysates in vitro and efficiently
ing of protein expression and provide the potential forcross cell membranes to function in protein synthesis
both spatial and temporal resolution. Here, we demon-in vivo as indicated by flow cytometry, selective en-
strate that a variety of puromycin conjugates can berichment studies, and Western analysis. Overall, this
used as detectors of protein synthesis in live cells. Thiswork demonstrates that fluorescent-puromycin con-
work shows that puromycin conjugates can easily enterjugates offer a general means to examine protein ex-
cells and covalently label newly synthesized proteins,pression in vivo.
enabling direct detection of protein expression in vivo.
Introduction
Results
Complete sequencing of the human genome [1, 2] shows
that less than 50% of the putative gene transcripts corre- Design of Puromycin Conjugates
spond to known proteins. A complete understanding of To label newly synthesized proteins, our puromycin con-
the proteome awaits the identification of thousands of jugates would have to satisfy three general criteria: (1)
unassigned gene products and assignment of their role functionality in peptide bond formation, (2) cell perme-
in signaling cascades [3], membrane trafficking [4], apo- ability, and (3) ready detection in a cellular or biochemi-
ptosis [5], and other cellular processes. Currently, there cal context. In addressing the first issue, it had been
are large-scale techniques to study cellular protein lev- previously shown that puromycin derivatives bearing sub-
els indirectly using DNA and mRNA arrays [6]. However, stitutions directly off the 5 OH functioned poorly in vitro
these techniques do not directly monitor the level of (e.g., biotin-puromycin IC5054M) [14], whereas conju-
protein synthesis. Methods to directly monitor protein gates with the general form X-dC-puromycin (e.g., bio-
expression in vivo are extremely useful, particularly in tin-dC-puromycin) were substantially more effective
the study of higher organisms with many different cell (IC50 11 M) [14]. We therefore chose to design mole-
and tissue types. cules by varying the substituents appended to dC-puro-
Currently, protein expression is studied using pulse mycin (Figure 2A).
labeling with a radioactive tracer or by transformation In order to facilitate cellular entry and detection, we
with fluorescent reporters based on the green fluores- considered a number of factors including: (1) type and
cent protein (GFP) and mutants (BFP, CFP, and YFP) [7]. position of the label, (2) the linker between the label and
Pulse-labeling experiments typically require the cell(s) dC-puromycin, (3) background fluorescence properties,
to be destroyed and are not amenable to microscopy and (4) membrane permeability including net charge and
experiments with simultaneous protein synthesis detec- hydrophobicity. We then designed and synthesized vari-
tion. Genetically encoded GFP mutants and fusion pro- ous dC-puromycin conjugates to address these issues
teins have seen broad biological applications, including systematically. The first series of puromycin conjugates
study of Ca2 localization [8] protein tyrosine kinase (1, 3, 4, 6, 8; Figure 2A) either contain fluorescent dyes
activity [9] and mRNA trafficking and protein synthesis (compounds 1 and 4), biotin (compound 6), or both (com-
localization in cultured neurons [10, 11]. However, the pounds 3 and 8). Two different fluorescent dyes were
utilized (Cy5 and fluorescein) to provide detection at a
range of emissions. Biotin labels were introduced to*Correspondence: rroberts@caltech.edu
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Figure 1. Action of Puromycin and Puromycin Conjugates
(A) Puromycin (P) participates in peptide bond formation with the nascent polypeptide chain.
(B) Puromycin-dye conjugates, of the form X-dC-puromycin where X  fluorescein (F), are also active in translation and become covalently
linked to protein.
enable detection via Western blot analysis or affinity in Figures 2A and 2B (Figure 3B). Generally, the activity
of conjugates with the form X-dC-puromycin falls overpurification. We also prepared a series of compounds
a fairly narrow range in vitro, with IC50 values ranging(2, 5, 7, 9; Figure 2A) that lack the 3-amino acid moiety
from 4 to 30 M (Table 1). Also, control conjugatesto serve as negative controls.
that lack the amino acid moiety, e.g., Cy52A (2) andA second series of conjugates with a phosphonate
BF2A (9), show little ability to inhibit protein synthesislinkage between dC and puromycin were prepared to
even at high concentrations.examine whether reduction of charge would enhance
We next wished to confirm that our puromycin conju-cell membrane solubility and facilitate cellular entry (Fig-
gates could become covalently attached to proteinure 2B). Three compounds (10, 11, 12; Figure 2B) were
in vitro. To do this, we translated globin mRNA in theconstructed bearing fluorescein (10, F2P-Me), biotin (11,
presence of increasing concentrations of FB2P (3), aB2P-Me), or the hydrophobic dimethoxytrityl group
conjugate containing fluorescein and biotin moieties(DMT) and fluorescein (12, DMT-F2P-Me). A DMT bear-
(Figure 3C). Next, the concentration-dependent incorpo-ing fluorescein-dC-dA conjugate (DMT-F2A-Me) served
ration of FB2P was analyzed using neutravidin affinityas a negative control (13; Figure 2B). The DMT group was
chromatography of these same translation reactionsadded to gauge whether the addition of a hydrophobic
(Figure 3D). These data indicate that puromycin conju-group would further enhance entry into cells.
gates are incorporated efficiently over a broad concen-
tration range ranging from 2- to 3-fold below the IC50
Analysis of Puromycin-Conjugate Activity In Vitro to well above it. Thus, labeling is possible even at con-
We began our analysis by examining the activity of each centrations where protein synthesis is not greatly in-
of our conjugates in vitro for their ability to inhibit protein hibited.
translation. Previously, we had used this activity assay These observations support the development of a
to measure the IC50 for various puromycin conjugates broad range of puromycin-based reagents for two rea-
[14] and analogs [18] as well as to demonstrate a direct sons. First, compounds of the form X-dC-puromycin
relationship between the IC50 and the efficiency of pro- appear tolerant to a wide variety of substitutions, includ-
tein labeling [14]. High-resolution tricine-SDS gel data ing molecules containing more than one detection han-
corresponding to a typical IC50 determination are shown dle (e.g., BF2P and FB2P). Interestingly, even the methyl
for Cy52P (1) and Cy52A (2) (Figure 3A). Using this ap- phosphonate versions (F2P-Me, 10; B2P-Me, 11; DMT-
F2P-Me, 12) showed good levels of in vitro activity. Sec-proach, we measured IC50 values for the compounds
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Figure 2. Chemical Structure of Puromycin Conjugates and Controls
(A) Puromycin and negative control conjugates.
(B) Methyl phosphonate-based puromycin conjugates and negative control conjugates.
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Figure 3. In Vitro Activity Analysis for Various Puromycin Conjugates
(A) Tricine-SDS-PAGE analysis of globin translation reactions in the presence of Cy52P (1) (top) and Cy52A (2) (bottom): Lane 1, no template
and no conjugate; lane 2, globin alone; lanes 3 to 10, conjugate concentrations from 0.5 M to 120 M.
(B) Percent of globin translation relative to the no conjugate control for compounds 1, 2, 3, 4, 6, 8, 10, 11, and 12.
(C) Tricine-SDS-PAGE analysis of globin translation reactions incubated with increasing concentrations of FB2P (3): Lane 1, no template, no
conjugate; lane 2, globin alone; lane 3, 7 M; lane 4, 35 M; lane 5, 70 M; lane 6, 140 M; and lane 7, 210 M.
(D) Neutravidin-purified globin-FB2P complexes from translation reactions in (C).
ond, the IC50 values indicate that even modest concen- Analysis of Puromycin-Conjugate Activity In Vivo
In order to analyze the activity of puromycin conjugatestrations of each of these reagents in the low micromolar
range will be sufficient to achieve good levels of protein in vivo, we needed to choose both an appropriate cell
line and an appropriate quantitation and detectionlabeling. This is because our data here (Table 1, Figure
3) as well as previous data [14, 18] demonstrate that scheme. While microscopy is a powerful means to ana-
lyze individual cells and small sections of tissue, weprotein labeling is achieved at or below the IC50 value.
Thus, these in vitro translation and protein labeling wished to perform experiments where thousands to mil-
lions of cells could be examined for protein labeling. Weassays provide a starting concentration range for analy-
sis in live cells. therefore chose flow cytometry as our primary means
to analyze uptake and incorporation of our conjugates.
In addition to providing a quantitative measure of fluo-
Table 1. The Concentration of Puromycin Conjugate Required rescence and cell size, flow cytometry methods enable
for 50% Inhibition of Globin Translation (IC50). live cells and dead cells to be readily distinguished
Puromycin Conjugate IC50 (M) [19]. We chose the mammalian thymocyte D9 cell line
(16610D9) [20] for our experiment for four reasons: (1)(1) Cy52P 3.8
they have relatively uniform size and shape, (2) they do(2) Cy52A 100
(3) FB2P 24 not aggregate, making single cell detection possible, (3)
(4) F2P 22 they are suspension cells, which allows for ready growth
(6) B2P 15 in culture with subsequent acquisition of a large number
(8) BF2P 5.8 of single cell readings using flow cytometry, and (4)
(10) F2P-Me 25
they are amenable to routine infection techniques to(11) B2P-Me 16
introduce selectable markers and GFP-based tags.(12) DMT-F2P-Me 29
We began by comparing the concentration and time
In replicate experiments, the standard error is 5%.
dependence of labeling with F2P (4) and the negative
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Figure 4. Analysis of Puromycin Conjugate Activity in 16610D9 Thymocyte Cells
Dose-response analysis of 16610D9 thymocyte cells treated with F2P or F2A at (A) 5 M and (B) 25 M. Incubation times are 1 (blue), 7
(green), 24 (teal) and 48 (purple) hr. Untreated cells incubated for 1 hr are indicated with red.
Cells were analyzed using a flow cytometer and gated on a live cell population according to forward and side scatter plots.
(C) Flow cytometry analysis of: untreated cells (red); Fluorescein-puromycin, FP, (blue); F2P, 4 (light green); F2P-Me, 10, (orange); FB2P, 1,
(cyan); BF2P, 8, (fuchsia); DMT-F2P-Me, 12 (brown). Cells were incubated for 24 hr with puromycin conjugates at 50 M. Analysis was performed
using flow cytometry using a live cell gate as in (A) and (B). (D) Epi-fluorescence microcopy of D9 cells treated with DMT-F2P-Me (25 M)
with 200 magnification.
control conjugate F2A (5) (Figures 4A and 4B). For F2P, cell gate as before (Figure 4C). In this series, DMT-F2P-
Me (12) gives the strongest enhancement, and the rankprogressively increased fluorescence is seen with in-
creasing time, and the greatest enhancement is seen order of compounds follows DMT-F2P-Me (12)  FB2P
(3)  BF2P (8)  F2P (4)  F2P-Me (10)  FP. The IC50after the 24 hr incubation at both 5 M and 25 M of the
conjugate (Figures 4A and 4B). At both concentrations, values for all the compounds, with the exception of FP
(IC50 120M [14]), are relatively similar, while additiona substantial population of live cells is detected and
demonstrates up to 4-fold enhanced fluorescence rela- of the DMT group in compound (12) would be expected
to confer increased hydrophobicity and membrane per-tive to the F2A control molecule. Longer incubation (48
hr) in the presence of F2P eventually kills the majority meability. Compounds containing a phosphate [F2P (4)]
or a methylphosphonate [F2P-Me (10)] bridging the pu-of cells at both concentrations tested. In contrast, the
background fluorescence from F2A reaches a maximum romycin and dC residue show little difference in IC50
values (Figure 3B; Table 1) and in vivo labeling (Figureof 101 units after a 7 hr incubation for both 5 and 25
M incubations (Figures 4A and 4B), and F2A has no 4C), arguing that charge at this position does not play
a key role in either the activity as a substrate or entryapparent effect on cell viability. The fluorescence en-
hancement beyond 101 units for cells treated with F2P into the cell. The poor IC50 for FP in vitro [14] correlates
with the small fluorescence enhancement seen for thisis consistent with C-terminal protein labeling by the fluo-
rescein-puromycin conjugate. These experiments also compound in vivo (Figure 4C). Epifluorescence micros-
copy confirms that the conjugate DMT-F2P-Me (12)suggest that there is an optimum concentration and
incubation time for labeling expressed proteins without readily enters and labels D9 cells brightly (Figure 4D).
Following these experiments, we next wished to con-killing the cells.
We next wanted to examine the relative level of fluo- firm that two of the best compounds, BF2P (8) and DMT-
F2P-Me (12), also showed fluorescence enhancementrescence enhancement for a series of conjugates. To
do this, a uniform population of D9 cells was split into in vivo relative to control molecules containing only a
terminal adenosine. Indeed, comparison of cells treatedseparate containers, each containing identical concen-
trations of a different puromycin conjugate, incubated with BF2P (8) versus BF2A (9) (Figure 5A) and DMT-F2P-
Me (12) versus DMT-F2A-Me (13) (Figure 5B) indicatesfor 24 hr, and analyzed by flow cytometry with a live-
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Figure 5. Fluorescence Shift Analysis for Pu-
romycin Conjugates versus Negative Control
Molecules in 16610D9 Thymocyte Cells
(A) Untreated cells (red); BF2A, 9 (blue); BF2P,
8 (green).
(B) Untreated cells (red); DMT-F2A-Me, 13
(blue); DMT-F2P-Me, 12 (green).
Analysis was performed using flow cytometry
using a live cell gate as described for Figure 5.
that compounds bearing the terminal puromycin moiety Flow cytometry was used to both examine the infec-
tion efficiency and confirm the ability to perform puromy-show a 3- to 4-fold fluorescence enhancement as com-
cin-based enrichment. After infection with the MIG orpared with the control molecules. This shift in fluores-
MIGPAC vectors, 5.0% and 4.3% of the D9 cells werecence is consistent with labeling protein during rounds
infected and alive based on GFP expression, respec-of translation. Overall, the combination of our in vitro
tively (Figure 6B, upper panels). In both cases, the otherand in vivo observations is consistent with the notion
95% of the cells showed no GFP-based signal. Puromy-that the overall fluorescence enhancement reflects both
cin was then added to both MIG- and MIGPAC-infectedthe efficacy and the cellular permeability of the com-
cells followed by incubation for 48 hr at 37C. For MIG-pounds.
infected cells, puromycin results in almost complete kill-
ing of both GFP-positive and GFP-negative cells (Figure
Mechanism of Puromycin Conjugate 6B, lower left panel). For MIGPAC-infected cells, puro-
Activity In Vivo mycin selectively kills only those cells lacking GFP, such
We next wished to demonstrate that the puromycin con- that after 48 hr the population is totally dominated by
jugates we had constructed were acting in vivo by the GFP-positive cells (94%) (Figure 6B, lower right panel).
same mechanism as puromycin itself. Puromycin can Enrichment of GFP-positive cells occurs because they
be used as a selection agent in mammalian cell culture express the PAC resistance protein that acylates puro-
to kill cells that lack the resistance gene encoding puro- mycin, rendering it inactive. These experiments demon-
mycin N-acetyl-transferase (PAC) [21]. This enzyme N-acet- strate that puromycin acylation is sufficient to rescue
ylates the reactive amine on puromycin and blocks its cells from puromycin toxicity and that N-blocked puro-
ability to participate in peptide bond formation [22, 23]. mycin is non-toxic to D9 cells. The selective enrichment
In a mixed population of cells, those that lack a vector of PAC-expressing cells argues that puromycin exerts
expressing PAC can be selectively killed by long incuba- its effect on D9 cells by acting on the translation appara-
tions (	 48 hr) with puromycin, leaving only vector-con- tus in vivo.
taining cells alive. Previously, we showed that chemical We next wished to examine if B2P (6) could act in a
acylation inactivates puromycin-mediated translation biochemically similar fashion as puromycin itself. As
inhibition in vitro [14]. Thus, we wished to see if the D9 with puromycin, flow cytometry indicated that long ex-
cells bearing PAC would be resistant to killing (and thus posures of B2P (6) kills the vast majority of the cells
enriched in the mixed population) by long incubations infected with MIG (Figure 6C, bottom left panel), while
with puromycin itself or our puromycin conjugates B2A (7), a control molecule lacking the amino acid, had
in vivo. no effect (Figure 6C, middle left panel). Importantly, cells
Foreign genes can be inserted into D9 cells by infec- infected with MIGPAC show selective enrichment when
tion with a viral vector (see Experimental Procedures). incubated with B2P (6) (Figure 6C, bottom right panel),
Vectors that express GFP provide a straightforward while B2A shows no change in GFP-positive and nega-
means to measure the fraction of cells that become tive populations (Figure 6C, middle right panel). These
infected and a direct means to monitor any vector-medi- experiments are fully consistent with B2P (6) acting by
ated enrichment. We infected D9 cells with a viral vector the same mechanism as puromycin itself. Further, these
driven by a mouse stem cell virus promoter (MSCV) data also provide the first demonstration that PAC can
containing an internal ribosome entry site (IRES) up- act on puromycin conjugates bearing 5-extensions
stream from enhanced green fluorescent protein (EGFP) in vivo.
referred to as MIG (MIG  MSCV-IRES-GFP; Figure 6) In line with this conclusion, two other puromycin con-
[24]. MIG expresses GFP so that infection efficiency can jugates show similar activity with B2P. We examined a
be monitored by GFP fluorescence (Figure 6). A second Cy5-bearing conjugate Cy52P (1) and compared its ac-
vector containing the PAC gene was also constructed tion with an analogous control molecule, Cy52A (2), us-
(MIGPAC; Figure 6) and results in a bicistronic mRNA in ing both MIG- and MIGPAC-infected cells. Cy5 provides
a useful spectroscopic handle in this context becausewhich both PAC and GFP can be translated (Figure 6).
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Figure 6. In Vivo Mechanism of Action Studies with Puromycin, Puromycin Conjugates, and Controls
(A) D9 thymocyte cells were infected with MIG or MIGPAC constructs that express GFP.
(B) Cells infected with MIG are sensitive to puromycin action, whereas cells infected with MIGPAC are resistant to puromycin and thus
specifically enriched from 4.3% to 94% of the total population.
(C) Similarly, D9 cells infected with MIG are sensitive to puromycin conjugate B2P (6) but not B2A (7). MIGPAC-infected cells are unaffected
by B2A (7) but are resistant and specifically enriched by B2P (6).
its red-shifted fluorescence allows the emission of the Procedures). Proteins were run on a SDS-PAGE gel and
transferred to nitrocellulose. Equal protein loading wasconjugate to be unambiguously separated from that of
GFP. As with B2P versus B2A, MIG-infected cells were confirmed in each lane using Ponceau S (data not
shown). The Ponceau S stain was rinsed away, and theinsensitive to Cy52A, while long exposure of Cy52P
killed both GFP-positive and -negative populations, blot was probed with an anti-fluorescein antibody to
detect any fluorescein-conjugated protein containingsince they lacked the PAC resistance determinant (data
not shown). Cy52P also selectively enriched MIGPAC- BF2P or BF2A. Cells treated with BF2P (Figure 7, lane
2) show good levels of incorporation in this assay, whileinfected cells from 4.3% to 90% (data not shown). Addi-
tionally, B2PMe (11) also resulted in selective enrich- lanes with cells alone (lane 1), cells treated with BF2A
(lane 3), or anisomycin (lane 4) show essentially no sig-ment of MIGPAC-bearing cells and had similar potency
with B2P (6) (data not shown). Taken together, these nal. The Western blot analysis of BF2P thus shows good
correlation with flow cytometry data and is consistentdata support the idea that our various X-dC-puromycin
conjugates act by the same mechanism as puromycin with a model where puromycin conjugates are stably
incorporated into proteins in vivo during protein syn-in vivo and that conjugates lacking the 3-amino acid
moiety have no effect. thesis.
DiscussionWestern Blot Analysis of Puromycin Conjugate
Labeling in Live Cells
Action of puromycin and our conjugates should result In the present study, we developed a technique to detect
protein synthesis in live cells that does not require genein proteins bearing these compounds at their C terminus
in vivo. We chose to use Western blot analysis of cellular transfection or radiolabeling. Our strategy thus provides
an important potential alternative to these methods forlysates to examine if incorporation occurred in vivo and
compare the resulting signal with our control conju- studying protein expression in vivo. Generally, a great
diversity of reagents of the class X-dC-puromycin,gates. Cells were incubated with either BF2P (8) or the
control molecule BF2A (9), washed, and a whole-cell where X can be one or two fluorescent or affinity tags,
can be constructed and show good activity in proteinlysate was prepared for each sample (see Experimental
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can be photoactivated or presented as pro-drugs may
provide useful paths for future conjugate development.
The general class of compounds described here should
therefore serve as useful cell biology tools to evaluate
in vivo protein synthesis in areas such as nuclear protein
synthesis [26, 27], neuron dendritic protein synthesis
[10], dendritic cell aggresome-like induced structures
(DALIS) [28], and other novel proteome functions.
Significance
Existing methods to study in vivo protein synthesis
Figure 7. Western Analysis of 16610D9 Thymocyte Cells Treated generally require choice of a candidate gene, radioac-
with a Puromycin Conjugate and Analyzed Using an 
-Fluorescein
tivity, or the destruction of cells. To overcome theseAntibody
limitations, we have developed a new class of reagentsLane 1, untreated cells; lane 2, BF2P, 8 (25 M); lane 3, BF2A, 9 (25
that enable detection of protein synthesis in live cellsM); and anisomycin (250 ng/ml). Ponceau S stain was used to
using fluorescent and biotinylated puromycin conju-confirm equal protein loading. BF2P-conjugated protein is seen at
many molecular weights indicating that the conjugate could target gates. These reagents, of the general form X-dC-puro-
all translating ribosomes. mycin, are active in vitro and in vivo and provide a
nontoxic alternative for the study of protein synthesis
in live cells. A wide variety of detection moieties appear
synthesis in vitro and in vivo. These reagents all appear to be accommodated at the X-position allowing for
to act by the same basic mechanism, entering the ribo- facile custom reagent design and development. Initial
somal peptidyl transferase site during translation, fol- in vitro studies correlate the function of our com-
lowed by covalent attachment to proteins being actively pounds in peptide bond formation during protein syn-
synthesized. Ribosome entry and attachment occurs thesis. Subsequent in vivo experiments in a mouse
predominantly at a few discrete sites in the open reading thymocyte cell line demonstrate the usefulness of
frame including the stop codon, rather than at every these molecules as indicators of protein synthesis in
position in the chain [14,25]. Previous work also demon- live cells. Selective enrichment studies with several
strates that over a 50-fold concentration range that conjugates as well as Western analysis demonstrate
brackets the IC50, the length of truncated products is that these compounds all label protein in cells by the
the same and that shorter products are favored as the same general mechanism, attachment to nascent pro-
conjugate concentration is increased substantially. teins during translation. The present results thus pro-
Despite the intermediate size of these molecules (1163 vide evidence that puromycin conjugates may serve
to 1730 Da), all the conjugates appear to be competent as an alternative to existing tools to elucidate the pro-
to enter the D9 suspension tissue culture cells used teome.
here and act at modest concentrations (5–25 M). Ex-
periments with other mammalian and insect cell types Experimental Procedures
support the idea that the ability of these compounds to
Materialscross membranes and act in protein synthesis is a gen-
L-Puromycin hydrochloride, rabbit globin mRNA, and carboxypepti-eral phenomenon (W.B. Smith, E. Schuman, B. Hay, per-
dase Y (CPY) were obtained from Sigma Chemical Co. (St. Louis,
sonal communication). MO). Rabbit reticulocyte Red Nova lysate was purchased from No-
All of the conjugates we have examined show a signifi- vagen (Madison, WI). L-[35S]methionine ([35S]Met) (1175 Ci/mmol)
cant and measurable shift in the fluorescence intensity was obtained from NEN Life Science Products (Boston, MA). Immu-
nopure immobilized Neutravidin-agarose was from Pierce (Rock-of live cells as compared to the control conjugates.
ford, IL). GF/A glass microfiber filters were from Whatman.Western analysis and selective enrichment studies sup-
port the idea that this shift is due to the specific covalent
Puromycin Conjugatesattachment of the conjugates to nascent proteins during
Puromycin conjugates were synthesized using standard phosphor-
translation. Demonstration that affinity tags may be in- amidite chemistry at the California Institute of Technology oligonu-
serted into expressed proteins in vivo provides the fu- cleotide synthesis facility. Puromycin-CPG was obtained from Glen
Research (Sterling, VA). Oligonucleotides were synthesized with theture opportunity to examine protein expression in re-
5-trityl intact, desalted via OPC cartridge chromatography (Glensponse to various cellular stimuli and subsequent
Research) (DNA oligonucleotides only), cleaved, and evaporated toidentification of the individual polypeptides through a
dryness. 5-biotin phosphoramidite, biotin phosphoramidite, 5-flu-combination of affinity purification and mass spectrom-
orescein phosphoramidite, and 6-fluorescein phosphoramidite (Glen
etry-based sequence analysis. Research) were used to make the biotin- and dye-puromycin conju-
In the short term (24 hr), these compounds are non- gates. Ac-dC-Me-phosphonamidite (Glen Research) was used to
prepare the phosphonate puromycin conjugates. The dried samplestoxic based on the proportion of live cells seen in our
were resuspended and desalted on Sephadex G-25 (Sigma). Puro-flow cytometry experiments. The robust labeling and
mycin, puromycin-conjugate, and control molecule concentrationssignal to noise ratio we observe thus makes these com-
were determined with the following extinction coefficientspounds useful for a great diversity of cell-, tissue-, and
(M1cm1): puromycin (260  11,790; in H2O); B2P and B2P-Meorganism-level experiments. The long-term toxicity of (260  19,100; in H2O); F2P, F2PMe, DMT-F2P-Me, FB2P, BF2P,
the present set of compounds may provide some limita- F2A, and BF2A (471 66,000; in 1PBS); Cy52P and Cy52A (650
250,000; in 1 PBS).tions for their use. In that context, nontoxic variants that
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In Vitro Potency Determination for Puromycin Conjugates twice in PBS. Live cell number was determined using trypan blue
exclusion dye and each sample was adjusted to contain an equalTranslation reactions containing [35S]Met were mixed in batch on
ice and added in aliquots to microcentrifuge tubes containing an number of live cells. Cell pellets were resuspended in 2 lysis buffer
(100 mM -glycerophosphate, 3 mM EGTA, 2 mM EDTA, 0.2 mMappropriate amount of puromycin-conjugate (or control molecule)
dried in vacuo. Typically, a 20 l translation mixture consisted of sodium-orthovanadate, 2 mM DTT, 20 g/ml aprotinin, 20 g/ml
leupeptin, 50 g/ml trypsin inhibitor, 4 g/ml pepstatin, and 1%0.8l of 2.5 M KCl, 0.4l of 25 mM MgOAc, 1.6l of 12.5 translation
mixture without methionine, (25 mM dithiothreitol [DTT], 250 mM Triton X-100) and incubated on ice for 30 min. Cell debris was
removed by centrifugation at 20,000  g for 30 min. Cell lysate wasHEPES [pH 7.6], 100 mM creatine phosphate, and 312.5 M of 19
amino acids, except methionine), 3.6 l of nuclease-free water, 0.6 combined with SDS loading buffer (0.12 M Tris-Cl [pH 6.8], 20%
l (6.1 Ci) of [35S]Met (1175 Ci/mmol), 8 l of Red Nova nuclease- glycerol, 4% [w/v] SDS, 2% [v/v] -mercaptoethanol, and 0.001%
treated lysate, and 5 l of 0.05 g/L globin mRNA. Inhibitor, lysate bromophenol blue) and heated at 90C for 10 min. Samples were
preparation (including all components except template), and globin applied entirely to a 4% stacking portion of a 10% glycine-SDS-
mRNA were mixed simultaneously and incubated at 30C for 60 min. polyacrylamide gel (30 mA for 1h, 30 min). Protein was transferred
Each reaction (2 L) was combined with 8 l of tricine loading buffer using standard Western transfer transfer techniques and the blot
(80 mM Tris-Cl [pH 6.8], 200 mM DTT, 24% [v/v] glycerol, 8% sodium was probed with an anti-fluorescein antibody followed by an anti-
dodecyl sulfate [SDS], and 0.02% [w/v] Coomassie blue G-250), rabbit-horseradish peroxidase conjugate (Pierce chemicals).
heated to 90C for 5 min, and applied entirely to a 4% stacking The chemiluminescence reaction was carried out using the ECL
portion of a 15% tricine-SDS-polyacrylamide gel containing 20% PLUS Western Blotting Detection System (Amersham Biosciences).
(v/v) glycerol [29] (30 mA for 1h, 30 min). Gels were fixed in 10%
acetic acid (v/v) and 50% (v/v) methanol, dried, exposed overnight Acknowledgments
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